Low Serum or Plasma Sodium
Increase in extracellular fluid volume as produced by congestive heart failure, cirrhosis and ascites, producing dilutional hyponatremia
GI loss of sodium from vomiting, diarrhea, or malabsorption, especially with replacement of fluid and not electrolytes
Renal sodium loss from diuretic use or chronic renal insufficiency
Addison's disease producing adrenal insufficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH), as caused by a CNS lesion, pulmonary disease, carcinoma, porphyria
Suggested Additional Lab Testing
Tests for the presence of congestive heart failure and cirrhosis
Indicators of renal function, such as creatinine and BUN
Serum aldosterone level
Serum or plasma BUN, and urine sodium and osmolarity, are valuable in demonstrating hyponatremia and differentiating among the causes of hyponatremia.
In SIADH, both urine sodium and urine osmolarity are increased.
In the presence of a diuretic inducing hyponatremia, urine sodium is increased, but urine osmolarity is usually isotonic to plasma.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia